Redpin Therapeutics Inc., a New York-based preclinical gene therapy startup leveraging a chemogenetics approach to hard-to-treat CNS diseases, has highlighted a new paper in Science detailing the ion channel-based platform behind its nascent pipeline. The approach, the rights to which Redpin exclusively licensed from the Howard Hughes Medical Institute (HHMI), enables targeted cell activation or inhibition that can be controlled by low doses of the anti-smoking drug Chantix (varenicline), it said.